Aspergillus and CMV antigenemias in 35 transplant patients who received T-cell therapy and in 46 control transplant recipients. X axes: weeks after transplantation and number of evaluable patients at each time point. (A-B) Aspergillus galactomannan antigenemia in haploidentical recipients with evidence of aspergillosis (values > 1 ng/mL indicate invasive aspergillosis). In 13 control patients who did not receive adoptive therapy (A) galactomannan antigenemia remained high. In 10 patients who had received adoptive therapy (B) antigenemia normalized within a few weeks (P < .002 vs controls). Results are expressed as Aspergillus galactomannan content (ng/mL). (C-D) CMV antigenemia in haploidentical recipients (positive cell number per 200 000 total cells). In 33 control patients who did not receive adoptive therapy (C) CMV continued reactivating for several weeks after transplantation. In 25 patients who had received adoptive therapy (D) CMV antigenemia normalized soon after infusion (P = .002). All data are presented as mean ± SD.